Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor.

NCT03263767 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT03263767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03263767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor.
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
January 15, 2018
Completion date
June 21, 2022
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft versus host disease